Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aclarion, Inc. - Common Stock (NQ: ACON )

0.3255 -0.0001 (-0.03%)
Streaming Delayed Price Updated: 2:30 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aclarion, Inc. - Common Stock

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion, Inc. Announces Delayed 10-Q Filing
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Announces Participation at the NASS 37th Annual Meeting
Via ACCESSWIRE
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Via ACCESSWIRE
Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain
Via ACCESSWIRE
Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
Via ACCESSWIRE
Aclarion's Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV
Via ACCESSWIRE
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor
Via ACCESSWIRE
Aclarion, Inc. (NASDAQ: ACON) Featured in Coverage of Investor Summit Group’s Q3 Virtual Event
Via Investor Brand Network
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
Initial findings from the EVAL study are expected to be released in Q4 2022 
From Aclarion Inc.
Via AccessWire
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years 
From Aclarion Inc.
Via AccessWire
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering
SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy... 
From Aclarion Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence Legal Regulatory
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.